Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AURA NASDAQ:AVDL NASDAQ:GPCR NASDAQ:VCEL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAURAAura Biosciences$6.05+0.5%$6.45$4.34▼$12.38$375.83M0.45290,833 shs191,865 shsAVDLAvadel Pharmaceuticals$15.01+0.5%$14.22$6.38▼$16.66$1.46B1.461.36 million shs1.28 million shsGPCRStructure Therapeutics$27.28+2.5%$20.61$13.22▼$43.46$1.57B-1.651.00 million shs948,282 shsVCELVericel$32.44+2.9%$34.46$29.24▼$63.00$1.64B1.39933,894 shs485,017 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAURAAura Biosciences0.00%-1.79%-6.64%-1.79%-30.62%AVDLAvadel Pharmaceuticals0.00%-2.15%-4.76%+68.84%+14.67%GPCRStructure Therapeutics0.00%+9.12%+23.55%+45.65%-36.54%VCELVericel0.00%+7.31%-4.73%-17.69%-25.18%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAURAAura Biosciences$6.05+0.5%$6.45$4.34▼$12.38$375.83M0.45290,833 shs191,865 shsAVDLAvadel Pharmaceuticals$15.01+0.5%$14.22$6.38▼$16.66$1.46B1.461.36 million shs1.28 million shsGPCRStructure Therapeutics$27.28+2.5%$20.61$13.22▼$43.46$1.57B-1.651.00 million shs948,282 shsVCELVericel$32.44+2.9%$34.46$29.24▼$63.00$1.64B1.39933,894 shs485,017 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAURAAura Biosciences0.00%-1.79%-6.64%-1.79%-30.62%AVDLAvadel Pharmaceuticals0.00%-2.15%-4.76%+68.84%+14.67%GPCRStructure Therapeutics0.00%+9.12%+23.55%+45.65%-36.54%VCELVericel0.00%+7.31%-4.73%-17.69%-25.18%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAURAAura Biosciences 2.78Moderate Buy$22.00263.64% UpsideAVDLAvadel Pharmaceuticals 2.90Moderate Buy$20.8638.95% UpsideGPCRStructure Therapeutics 2.89Moderate Buy$68.67151.71% UpsideVCELVericel 2.50Moderate Buy$60.4086.19% UpsideCurrent Analyst Ratings BreakdownLatest AURA, VCEL, AVDL, and GPCR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/27/2025AURAAura BiosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025AVDLAvadel PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025GPCRStructure TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025VCELVericelWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)9/17/2025VCELVericelBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral9/8/2025GPCRStructure TherapeuticsLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy9/5/2025AVDLAvadel PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$24.00 ➝ $36.009/3/2025AVDLAvadel PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold9/3/2025AVDLAvadel PharmaceuticalsLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy9/2/2025AVDLAvadel PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageEqual Weight$16.008/21/2025AVDLAvadel PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$13.00 ➝ $20.00(Data available from 10/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAURAAura BiosciencesN/AN/AN/AN/A$3.04 per shareN/AAVDLAvadel Pharmaceuticals$169.12M8.62N/AN/A$0.77 per share19.49GPCRStructure TherapeuticsN/AN/AN/AN/A$15.10 per shareN/AVCELVericel$237.22M6.90$0.31 per share103.81$5.92 per share5.48Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAURAAura Biosciences-$86.92M-$1.96N/AN/AN/AN/A-64.44%-54.24%11/11/2025 (Estimated)AVDLAvadel Pharmaceuticals-$48.83M-$0.03N/A250.17N/A-1.32%-3.73%-1.73%11/11/2025 (Estimated)GPCRStructure Therapeutics-$122.53M-$1.05N/AN/AN/AN/A-21.31%-20.34%11/12/2025 (Estimated)VCELVericel$10.36M$0.12270.3673.73N/A2.85%2.47%1.69%11/6/2025 (Estimated)Latest AURA, VCEL, AVDL, and GPCR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025AURAAura Biosciences-$0.49-$0.47+$0.02-$0.47N/AN/A8/7/2025Q2 2025AVDLAvadel Pharmaceuticals$0.02$0.10+$0.08$0.10$60.28 million$68.13 million8/6/2025Q2 2025GPCRStructure Therapeutics-$0.28-$0.36-$0.08-$0.36N/AN/A7/31/2025Q2 2025VCELVericel-$0.04-$0.01+$0.03-$0.01$64.61 million$63.24 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAURAAura BiosciencesN/AN/AN/AN/AN/AAVDLAvadel PharmaceuticalsN/AN/AN/AN/AN/AGPCRStructure TherapeuticsN/AN/AN/AN/AN/AVCELVericelN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAURAAura BiosciencesN/A12.3912.39AVDLAvadel PharmaceuticalsN/A2.792.38GPCRStructure TherapeuticsN/A20.4820.48VCELVericelN/A4.974.56Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAURAAura Biosciences96.75%AVDLAvadel Pharmaceuticals69.19%GPCRStructure Therapeutics91.78%VCELVericelN/AInsider OwnershipCompanyInsider OwnershipAURAAura Biosciences6.30%AVDLAvadel Pharmaceuticals5.20%GPCRStructure Therapeutics5.60%VCELVericel7.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAURAAura Biosciences5062.12 million58.21 millionNot OptionableAVDLAvadel Pharmaceuticals7097.10 million92.05 millionOptionableGPCRStructure Therapeutics13657.60 million54.37 millionOptionableVCELVericel30050.46 million46.83 millionOptionableAURA, VCEL, AVDL, and GPCR HeadlinesRecent News About These CompaniesVericel Corporation $VCEL Shares Purchased by PFG Investments LLCOctober 4 at 3:45 AM | marketbeat.comCanaccord Genuity Keeps Their Buy Rating on Vericel (VCEL)September 26, 2025 | theglobeandmail.comVericel Corporation $VCEL Shares Acquired by Congress Asset Management Co.September 26, 2025 | marketbeat.comVericel (NASDAQ:VCEL) Hits New 12-Month Low - Time to Sell?September 25, 2025 | marketbeat.comKopp Family Office LLC Sells 8,554 Shares of Vericel Corporation $VCELSeptember 24, 2025 | marketbeat.comVoya Investment Management LLC Purchases 10,048 Shares of Vericel Corporation $VCELSeptember 24, 2025 | marketbeat.com18,200 Shares in Vericel Corporation $VCEL Purchased by Strs OhioSeptember 20, 2025 | marketbeat.comDeclining Stock and Decent Financials: Is The Market Wrong About Vericel Corporation (NASDAQ:VCEL)?September 18, 2025 | finance.yahoo.comVericel (NASDAQ:VCEL) Shares Gap Down After Analyst DowngradeSeptember 18, 2025 | marketbeat.comVericel (NASDAQ:VCEL) Downgraded to Neutral Rating by BTIG ResearchSeptember 18, 2025 | marketbeat.comVericel (NASDAQ:VCEL) Reaches New 52-Week Low on Analyst DowngradeSeptember 18, 2025 | marketbeat.comVericel downgraded to Neutral from Buy at BTIGSeptember 17, 2025 | msn.comBTIG Downgrades Vericel (VCEL)September 17, 2025 | msn.comIntech Investment Management LLC Buys 18,274 Shares of Vericel Corporation $VCELSeptember 17, 2025 | marketbeat.comVericel Corporation (NASDAQ:VCEL) Given Average Recommendation of "Buy" by BrokeragesSeptember 16, 2025 | marketbeat.comVericel (NASDAQ:VCEL) Shares Down 5.8% - Here's WhySeptember 12, 2025 | marketbeat.comHere’s Why Vericel Corp. (VCEL) Traded Down in Q2September 12, 2025 | msn.comJacobs Levy Equity Management Inc. Purchases Shares of 62,938 Vericel Corporation $VCELSeptember 12, 2025 | marketbeat.comIs the Options Market Predicting a Spike in Vericel Stock?September 11, 2025 | zacks.comVericel (NASDAQ:VCEL) Reaches New 52-Week Low - Should You Sell?September 10, 2025 | marketbeat.comAdage Capital Partners GP L.L.C. Sells 25,600 Shares of Vericel Corporation $VCELSeptember 10, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025The Fed Cut Rates: What Now for the S&P 500 and Equity Markets?By Thomas Hughes | September 18, 2025Why Datavault May Be the Penny AI Stock Investors Have Waited ForBy Nathan Reiff | September 22, 2025Darden Restaurants: A Textbook Buy-the-Dip OpportunityBy Thomas Hughes | September 19, 2025Sprouts, Darden Offer High-Upside Setups for Risk-TakersBy Sam Quirke | September 26, 2025AURA, VCEL, AVDL, and GPCR Company DescriptionsAura Biosciences NASDAQ:AURA$6.05 +0.03 (+0.50%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$6.16 +0.11 (+1.74%) As of 10/3/2025 06:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.Avadel Pharmaceuticals NASDAQ:AVDL$15.01 +0.07 (+0.47%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$15.00 -0.02 (-0.10%) As of 10/3/2025 05:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.Structure Therapeutics NASDAQ:GPCR$27.28 +0.66 (+2.48%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$26.58 -0.71 (-2.58%) As of 10/3/2025 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.Vericel NASDAQ:VCEL$32.44 +0.92 (+2.92%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$33.32 +0.88 (+2.70%) As of 10/3/2025 05:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Cheap Chipotle? Why CMG Stock Could Be Ready for a Comeback Alphabet: After Its Best Quarter in Decades, Is It Time to Buy? After Trump Deal, Can Meta Stock Withstand TikTok’s Onslaught? Starbucks Stock Slumps; This Competitor Shows Strength How Berkshire's OxyChem Buy Cements Its Long-Term Strength The Trade Desk: 2 Signs of a Comeback, 1 Risk Ahead NVIDIA Breaks Out to New Highs: What Comes Next? Down 22% From Highs, ServiceNow Could Be Too Cheap to Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
